Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation

This publication has 48 references indexed in Scilit:

• Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study
  Journal of Clinical Oncology, 2006
• Prognosis in Therapy-Related Acute Myeloid Leukemia and Impact of Karyotype
  Journal of Clinical Oncology, 2004
• Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin’s Disease: A Report From the German Hodgkin’s Lymphoma Study Group
  Journal of Clinical Oncology, 2003
• Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series
  Blood, 2003
• Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001
  Leukemia, 2002
• Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
  Blood, 2002
• A Proportional Hazards Model for the Subdistribution of a Competing Risk
  Journal of the American Statistical Association, 1999
• Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia
  Bone Marrow Transplantation, 1997
• AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial
  British Journal of Haematology, 1989
• A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
  The Annals of Statistics, 1988